Effects of Eligibility Criteria on Patient Selection and Treatment Implications from 10 Multidomain Dementia Prevention Trials: A Population-Based Study
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Introduction: Dementia prevention trials have so far shown little benefit of multidomain interventions against cognitive decline. Recruitment strategies in these trials often centre around dementia risk or cardiovascular risk profile, but it is uncertain whether this leads to inclusion of individuals who may benefit most from the intervention. We determined the effects of eligibility criteria on the recruitment of potential trial participants in the general population. Methods: In a systematic search until January 1, 2022, we identified all published and ongoing large (≥500 participants), phase-3 multidomain trials for the prevention of cognitive decline or dementia. We applied trial eligibility criteria to 5,381 participants of the population-based Rotterdam Study (mean age: 72 years, 58% women), to compare participant characteristics, predicted risk of cardiovascular disease, and dementia risk, between trial eligible and ineligible persons. Results: We identified 10 trials, of which 5 had been published (DR’s EXTRA, FINGER, preDIVA, MAPT, and HATICE) and 5 are ongoing (US-POINTER, MIND-CHINA, MYB, AgeWell.de, and J-Mint). Among all Rotterdam Study participants, eligibility across published trials ranged from 48% for MAPT to 87% for preDIVA, in line with original trial reports. Variability in eligibility was wider for ongoing trials, from 1% for US-POINTER to over 94% for MYB trial. Over 70% of trial eligible individuals are recommended preventive intervention in routine care based on their cardiovascular risk, similar for lipid-lowering (71%) and blood pressure-lowering treatment (73%). Ten-year risks of dementia were similar for eligible compared to ineligible individuals (12 vs. 11%). Conclusion: Multidomain dementia prevention trials fail to preferentially include those at the highest risk of dementia and mostly include individuals who qualify for interventions already on the basis of cardiovascular prevention guidelines. These findings call for better targeted enrolment of individuals for whom trial results can improve clinical decision-making.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A systematic review reported that the 10-year dementia risk for individuals eligible for four large-scale trials of multidomain (2+ domains) interventions(228, 261, 262, 264, 270) was similar to those deemed ineligible”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [271]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430
RetractedMach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project
Conroy, R. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00114-3 · Cited by 5,290
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
(2019) · doi:10.1161/cir.0000000000000677 · Cited by 4,501
Ngandu, T., Lehtisalo, J., Solomon, A., Levälahti, E., Ahtiluoto, S., Antikainen, R., Bäckman, L., Hänninen, T., Jula, A., Laatikainen, T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60461-5 · Cited by 3,689
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.010 · Cited by 1,896
Williamson (2019) · doi:10.1001/jama.2018.21442 · Cited by 1,246
Andrieu, S., Guyonnet, S., Coley, N., Cantet, C., Bonnefoy, M., Bordes, S., Bories, L., Cufi, M.-N., Dantoine, T., Dartigues, J.-F., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30040-6 · Cited by 838
A note on competing risks in survival data analysis
Satagopan, J. M., Ben-Porat, L., Berwick, M., Robson, M., Kutler, D., & Auerbach, A. D. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602102 · Cited by 745
SCORE2-OP working group and ESC Cardiovascular risk collaboration, de Vries, T. I., Cooney, M. T., Selmer, R. M., Hageman, S. H. J., Pennells, L. A., Wood, A., Kaptoge, S., Xu, Z., Westerink, J., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab312 · Cited by 622
van Charante, E. P. M., Richard, E., Eurelings, L. S., van Dalen, J.-W., Ligthart, S. A., van Bussel, E. F., Hoevenaar-Blom, M. P., Vermeulen, M., & van Gool, W. A. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30950-3 · Cited by 611
World‐Wide FINGERS Network: A global approach to risk reduction and prevention of dementia
Kivipelto, M., Mangialasche, F., Snyder, H. M., Allegri, R., Andrieu, S., Arai, H., Baker, L., Belleville, S., Brodaty, H., Brucki, S. M., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12123 · Cited by 553
Objectives, design and main findings until 2020 from the Rotterdam Study
Ikram, M. A., Brusselle, G., Ghanbari, M., Goedegebure, A., Ikram, M. K., Kavousi, M., Kieboom, B. C. T., Klaver, C. C. W., de Knegt, R. J., Luik, A. I., et al. (2020) · European Journal of Epidemiology · doi:10.1007/s10654-020-00640-5 · Cited by 452
Self-citationEpidemiology of Vascular Dementia: Nosology in a Time of Epiomics
Wolters, F. J., & Ikram, M. A. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.311908 · Cited by 403
Self-citationRosenberg, A., Mangialasche, F., Ngandu, T., Solomon, A., & Kivipelto, M. (2020) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2019.41 · Cited by 316
de Bruijn, R. F., Bos, M. J., Portegies, M. L., Hofman, A., Franco, O. H., Koudstaal, P. J., & Ikram, M. A. (2015) · BMC Medicine · doi:10.1186/s12916-015-0377-5 · Cited by 270
Self-citationPreventing Alzheimer's disease and cognitive decline.
(2010) · PubMed Central · Cited by 259
Soininen, H., Solomon, A., Visser, P. J., Hendrix, S. B., Blennow, K., Kivipelto, M., Hartmann, T., Hallikainen, I., Hallikainen, M., Helisalmi, S., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30332-0 · Cited by 241
Emberson, J. (2004) · European Heart Journal · doi:10.1016/j.ehj.2003.11.012 · Cited by 239
Multi-domain interventions for the prevention of dementia and cognitive decline
Hafdi, M., Hoevenaar-Blom, M. P., & Richard, E. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013572.pub2 · Cited by 124
Baker, L. D., Snyder, H. M., Espeland, M. A., Whitmer, R. A., Kivipelto, M., Woolard, N., Katula, J. A., Papp, K. V., Ventrelle, J., Graef, S., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13365 · Cited by 121
Stephan, B. C. M., Pakpahan, E., Siervo, M., Licher, S., Muniz-Terrera, G., Mohan, D., Acosta, D., Rodriguez Pichardo, G., Sosa, A. L., Acosta, I., et al. (2020) · The Lancet Global Health · doi:10.1016/s2214-109x(20)30062-0 · Cited by 111
Self-citationLicher, S., Yilmaz, P., Leening, M. J. G., Wolters, F. J., Vernooij, M. W., Stephan, B. C. M., Ikram, M. K., & Ikram, M. A. (2018) · European Journal of Epidemiology · doi:10.1007/s10654-018-0403-y · Cited by 102
Self-citationRichard, E., Jongstra, S., Soininen, H., Brayne, C., Moll van Charante, E. P., Meiller, Y., van der Groep, B., Beishuizen, C. R. L., Mangialasche, F., Barbera, M., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010806 · Cited by 92
Heffernan, M., Andrews, G., Fiatarone Singh, M. A., Valenzuela, M., Anstey, K. J., Maeder, A. J., McNeil, J., Jorm, L., Lautenschlager, N. T., Sachdev, P. S., et al. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180572 · Cited by 80
Lifetime risk of common neurological diseases in the elderly population
Licher, S., Darweesh, S., Wolters, F., Fani, L., Heshmatollah, A., Mutlu, U., Koudstaal, P., Heeringa, J., Leening, M., Ikram, M., et al. (2018) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-318650 · Cited by 73
Self-citationZülke, A., Luck, T., Pabst, A., Hoffmann, W., Thyrian, J. R., Gensichen, J., Kaduszkiewicz, H., König, H.-H., Haefeli, W. E., Czock, D., et al. (2019) · BMC Geriatrics · doi:10.1186/s12877-019-1212-1 · Cited by 71
Multi-domain interventions for the prevention of dementia and cognitive decline
Hafdi, M., Hoevenaar-Blom, M. P., & Richard, E. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013572 · Cited by 65
Komulainen, P., Kivipelto, M., Lakka, T. A., Savonen, K., Hassinen, M., Kiviniemi, V., Hänninen, T., & Rauramaa, R. (2010) · European Geriatric Medicine · doi:10.1016/j.eurger.2010.08.001 · Cited by 62
van Blijderveen, J. C., Straus, S. M. J. M., Zietse, R., Stricker, B. H. C., Sturkenboom, M., & Verhamme, K. M. C. (2013) · International Urology and Nephrology · doi:10.1007/s11255-013-0563-3 · Cited by 52
Sugimoto, T., Sakurai, T., Akatsu, H., Doi, T., Fujiwara, Y., Hirakawa, A., Kinoshita, F., Kuzuya, M., Lee, S., Matsuo, K., et al. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2021.29 · Cited by 47
Cited by
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01296-0 · Cited by 3,860
Brodaty, H., Chau, T., Heffernan, M., Ginige, J. A., Andrews, G., Millard, M., Sachdev, P. S., Anstey, K. J., Lautenschlager, N. T., McNeil, J. J., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03351-6 · Cited by 108
Whitmer, R. A., Baker, L. D., Carrillo, M. C., Snyder, H. M., Cleveland, M. L., Gitelman, D. R., Kivipelto, M., Leng, X., Lovato, L., Papp, K. V., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70351 · Cited by 19
Interventions to prevent dementia should target those at high risk
Livingston, G., & Costafreda, S. G. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01472-1 · Cited by 13
Demnitz‐King, H., Adeleke, M., Barber, J., Poppe, M., Budgett, J., Alberts, S., Duffy, L., Minihane, A. M., Gillings, R., Chapman, H., et al. (2025) · The Lancet Healthy Longevity · doi:10.1016/j.lanhl.2025.100777 · Cited by 15
Metadata
- Authors
- Licher, S., Wolters, F. J., Pavlović, J., Kavousi, M., Leening, M. J. G., Ikram, M. K., & Ikram, M. A.
- Affiliations
- Erasmus MC (NL)
- Corresponding author
- Licher, Silvan
- ORCID
- Venue
- Neuroepidemiology
- Publisher
- S. Karger AG
- Published
- 2022-11-17
- Volume
- 57
- Issue
- 1
- Pages
- 14-24
- ISSN
- 0251-5350 (ISSN-L)
- 1423-0208
- PMC
- PMC10064383
- OpenAlex
- W4309263713
- Cited by
- 13
- References
- 32
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 3 · 2023: 1
- FWCI
- 1.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (vor)
- creativecommons.org/licenses/by-nc/4.0/ (tdm)
- Locations
- Neuroepidemiology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by-nc)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Cognitive Abilities and Testing
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research
- Keywords
- dementia prevention, eligibility criteria, trial recruitment, multidomain intervention, cognitive decline, cardiovascular risk, dementia risk, Rotterdam Study, cardiovascular prevention guidelines, lipid-lowering therapy, blood pressure-lowering treatment
- MeSH terms
- Aged, Cardiovascular Diseases, Dementia, Female, Humans, Male, Research Design, Patient Selection, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.